[Clinical study of human pancreatic cancer-associated antigen (SPan-1 antigen) in hepatobiliary and pancreatic diseases].

Abstract

We studied clinical significance of serum SPan-1 antigen, which is human pancreatic cancer associated antigen, in hepatobiliary and pancreatic diseases employing newly developed kit. The sensitivity of serum SPan-1 antigen levels for pancreatic cancer, gallbladder carcinoma, hepatocellular carcinoma, bile duct cancer were 90.9%, 77.8%, 60.7%, 60.0% respectively. No correlation was found between serum SPan-1 antigen levels and total bilirubin levels. SPan-1 positivity in patients with hepatic disease including hepatocellular carcinoma was rather high, but there were few cases more than 100 U/ml. The mechanism of the elevated level was supposed to be release of the antigen from bile-duct epithelium, and this must be taken into consideration at diagnosis referred to serum SPan-1 antigen level.

• Authors: B Nakata, Y S Chung, H Yokomatsu, H Tanaka, T Sawada, H Nishiwaki, K Satake, K Umeyama, S Seki
• Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology (Nihon Shokakibyo Gakkai Zasshi) Vol. 87 Issue 4 Pg. 1050-5 (Apr 1990) ISSN: 0446-6586 [Print] Japan
• PMID: 2376901 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, Neoplasm
• pancreatic associated antigen, SPan-1

Topics

• Antigens, Neoplasm (analysis)
• Biliary Tract Diseases (immunology)
• Humans
• Liver Diseases (immunology)
• Pancreatic Diseases (immunology)